None

Mylan Pharmaceuticals receives FDA approval for pioglitazone tablets to treat type 2 diabetes

The U.S. Food and Drug Administration today approved the first generic version of Actos (pioglitazone hydrochloride) tablets. Along with diet and exercise, pioglitazone is used to improve blood glucos...

Human medicines European Public Assessment Report (EPAR): Glidipion (previously Pioglitazone Actavis Group), pioglitazone, Revision: 1, Authorised

Observational study designs

Researchers investigated whether pioglitazone was associated with an increased risk of bladder cancer in people with type 2 diabetes.1 Use of pioglitazone, an oral antidiabetic agent in the...

Pioglitazone Raises Bladder Cancer Risk In Diabetes Patients

Patients with type 2 diabetes who take medication pioglitazone have a higher risk of incident bladder cancer than diabetes patients who do not, researchers from McGill University, Canada, reported in...

FDA approves Mylan ANDA for Pioglitazone tablets

Mylan Pharmaceuticals has won final FDA approval for its abbreviated new drug application (ANDA) for Pioglitazone tablets USP, 15mg, 30mg and 45mg.

Ranbaxy launches Pioglitazone in US

Ranbaxy Pharmaceuticals, a wholly owned subsidiary of Ranbaxy Laboratories (RLL), has launched authorized generic pioglitazone hydrochloride tablets in the US market under an agreement with Takeda Pha...

Generic Actos enters US market

The US FDA granted its OK to Mylan Pharmaceuticals to market the first generic version of pioglitazone in the US. Along with diet and exercise, pioglitazone is used to improve blood glucose contro...

Cannabis Withdrawal Symptoms Might Have Clinical Importance - Certain Withdrawal Symptoms Are More Correlated To Risk Of Relapse

Cannabis users have a greater chance of relapse to cannabis use when they experience certain withdrawal symptoms, according to research published Sep. 26 in the open access journal PLOS ONE led by Dav...

Pioglitazone potentiates development of morphine-dependence in mice: Possible role of NO/cGMP pathway.

Peroxizome proliferator-activated receptor gamma (PPARγ) is highly expressed in the central nervous system where it modulates numerous gene transcriptions. Nitric oxide synthase (NOS) expression coul...

Pioglitazone upregulates adiponectin receptor 2 in 3T3-L1 adipocytes.

Pioglitazone, a full peroxisome proliferator-activated receptor (PPAR)-γ agonist, improves insulin sensitivity by increasing circulating adiponectin levels. However, the molecular mechanisms by which...

Evaluation of vitamin B12 effects on DNA damage induced by pioglitazone.

Pioglitazone is a prototype of thiazolidinediones, used for the treatment of type 2 diabetes mellitus. Previous studies suggest that pioglitazone might cause DNA damage by generation of oxidative spec...

Sub-chronic treatment with pioglitazone exerts anti-convulsant effects in pentylenetetrazole-induced seizures of mice: The role of nitric oxide.

Pioglitazone delayed the development of seizure responses and shortened the duration of convulsion of genetically epileptic EL mice. The anti-epileptic effect of pioglitazone was attributed partly thr...

NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice.

RATIONALE: Previously, we showed that pioglitazone exerts its antidepressant-like effect through peroxisome proliferator-activated receptor gamma receptors and demonstrated the possible involvement of...